SCHEMBL5512232

SCHEMBL5512232

CCCCCCCCCC([O])[O]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.52
LCK P06239 1/20 0.52
PPARD Q03181 1/20 0.52
ZDHHC20 Q5W0Z9 1/20 0.52
ZDHHC2 Q9UIJ5 1/20 0.52
ADH1B P00325 1/20 0.50
ADH1C P00326 1/20 0.50
ADH1A P07327 1/20 0.50
ADH4 P08319 1/20 0.50
ADH7 P40394 1/20 0.50
TSHR P16473 1/20 0.50
THRB P10828 1/20 0.50
ACE2 Q9BYF1 1/20 0.48
GPR84 Q9NQS5 3/20 0.48
FDPS P14324 3/20 0.48
SPHK1 Q9NYA1 1/20 0.48
FFAR1 O14842 1/20 0.48
CA1 P00915 1/20 0.48
LMNA P02545 1/20 0.48
DNM1 Q05193 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5509935 1.00 OPRM1 (0.52) OPRM1LCKPPARDZDHHC20ZDHHC2
SCHEMBL5505561 0.97
SCHEMBL7900423 0.87
SCHEMBL4641218 0.85 LCK (0.56) OPRM1LCKPPARDZDHHC20ZDHHC2
SCHEMBL3127346 0.85 LCK (0.56) OPRM1LCKPPARDZDHHC20ZDHHC2
SCHEMBL3620831 0.85 LCK (0.56) OPRM1LCKPPARDZDHHC20ZDHHC2
SCHEMBL8074338 0.85
SCHEMBL1882258 0.85 LCK (0.56) OPRM1LCKPPARDZDHHC20ZDHHC2
SCHEMBL3882931 0.85 LCK (0.56) OPRM1LCKPPARDZDHHC20ZDHHC2
SCHEMBL4643368 0.85 LCK (0.56) OPRM1LCKPPARDZDHHC20ZDHHC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157442-B2 Antibacterial compound SANKYO COMPANY, LIMITED (JP) 2007-01-02 US disclosed
EP-1209166-B1 NOVEL A-500359 DERIVATIVES SANKYO CO (JP) 2004-03-31 EP disclosed
US-20030171330-A1 Antibacterial compound SANKYO COMPANY, LIMITED (JP) 2003-09-11 US disclosed
EP-1209166-A1 NOVEL A-500359 DERIVATIVES Sankyo Company, Limited (JP) 2002-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171330-A1 Antibacterial compound TLR1, MPO, O60361 OPRM1 75/4885LCK 1896/4885PPARD 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.